度普利尤单抗治疗中重度特应性皮炎的疗效分析

Analysis of Efficacy of Dupilumab in the Treatment of Moderate-to-severe Atopic Dermatitis

目的:研究度普利尤单抗治疗中重度特应性皮炎的临床疗效。方法:选取2021年4月-2022年10月于石河子大学第一附属医院皮肤科门诊及病房中确诊的中重度特应性皮炎患者,使用SCORAD和DLQI评分评估患者治疗后疗效,并与患者的BMI、有无合并疾病及发病部位进行相关性分析。结果:使用度普利尤单抗治疗后第2周SCORAD评分较基线相比平均下降了17.62%,第4、8和16周时分别下降33.84%、44.01%、63.25%;DLQI在基线平均值17,到第16周时降至6.97,平均降低了59.49%。SCORAD评分与DLQI的下降趋势高度相关,用药后二者的数值变化呈正相关。治疗过程中绝大部分不良反应可自行消退或对症治疗后缓解。结论:度普利尤单抗在临床上治疗中重度特应性皮炎的总体疗效好,明显改善患者瘙痒及提升其生活质量,是传统治疗不佳患者的新选择。

Objective:To investigate the efficacy of Dupilumab in the treatment of moderate to severe atopic dermatitis.Methods:Patients with moderate to severe atopic dermatitis diagnosed in the dermatology outpatient department and ward of the First Affiliated Hospital of Shihezi University Medical College,Xinjiang Province from April 2021 to October 2022 were selected.SCORAD score and DLQI were used to evaluate the curative effect after treatment,Correlation analysis was conducted with BMI of patients,whether there were concurrent diseases and the site of disease.Results:SCORAD score at week 2 after Dupilumab treatment decreased by 17.62%from baseline,33.84%at week 4,44.01%at week 8 and 63.25%at week 16,respectively,DLQI decreased from a baseline mean of 17 to 6.97 by week 16,a mean reduction of 59.49%.SCORAD score was highly correlated with DLQI score,and there was a positive correlation between the two data changes after medication.The vast majority of adverse reactions during the treatment process can self resolve or be relieved after symptomatic treatment.Conclusion:The overall efficacy of Dupilumab in the clinical treatment of moderate to severe atopic dermatitis is stable and safe.Dupilumab can significantly improve itching and patients'quality of life,which is a new choice for patients with poor traditional treatment.